Skip to Main Content

Paper Details

Survival outcomes and risk group validation from SWOG S0925: a randomized phase II study of cixutumumab in new metastatic hormone-sensitive prostate cancer.
Prostate Cancer Prostatic Dis
5
2020
PSA, androgen, hormone-sensitive prostate cancer, insulin-like growth factor I receptor, metastatic, metastatic hormone-sensitive prostate cancer, patients, prostate-specific antigen
Author NameAffiliation
Neeraj AgarwalHuntsman Cancer Institute, University of Utah
Heather H ChengUniversity of Washington
Heather H ChengClinical Research Division, Fred Hutchinson Cancer Research Center
Maha HussainFeinberg School of Medicine, Northwestern University
Ian M ThompsonCHRISTUS Santa Rosa Medical Center Hospital
David I QuinnNorris Comprehensive Cancer Center, University of Southern California
Evan Y YuUniversity of Washington
Evan Y YuClinical Research Division, Fred Hutchinson Cancer Research Center
  • 1 - 8

Datasets

Release 1.2